If you are reading this, you have probably already tried the standard routes. Maybe you are on your second or third antidepressant. Maybe they helped a little, or not at all. Maybe the side effects were their own problem. And you are still here, still struggling, wondering if there is something else.
There is. It is not a miracle cure. But it is real, it is growing, and in several European countries it is now accessible. This article will tell you what the research actually says — honestly, including the caveats — and what your options look like right now.
What is psilocybin-assisted therapy?
Psilocybin is the active compound in certain mushrooms. In a therapeutic setting, you take it once or twice, not every day, in a carefully prepared session, with a trained therapist or guide present throughout.
The drug is not the therapy. What makes it work is the combination of the substance, the preparation beforehand, the session itself, and the integration work that follows. Every study that has shown meaningful results has included all of these. You are not just swallowing something and waiting. You are doing real work, with support.
What the research says
For people who haven't responded to antidepressants
The most rigorous data comes from a company called COMPASS Pathways. They ran the largest clinical trials ever conducted with a classic psychedelic.
Their 2022 trial, published in the New England Journal of Medicine, enrolled 233 adults with treatment-resistant depression — meaning people who had already tried and failed at least two antidepressants. A single 25mg dose produced a significant reduction in depression scores at three weeks. 37% of participants met the criteria for response; 29% reached full remission.
In 2025 and 2026 they completed two Phase 3 trials — the most rigorous level of clinical testing. Both hit their primary endpoints. Effects from a single dose lasted through at least 26 weeks in one trial; the second trial's long-term data is coming later in 2026.
One honest caveat: the effect sizes in Phase 3 were real but modest — about 3.6–3.8 points on a depression scale that runs to 60. COMPASS also used a lower threshold for "response" in these trials than the standard clinical definition. The treatment works; it doesn't work equally well for everyone.
For people with depression who haven't tried everything yet
Two important studies looked at people with standard depression — not just the hardest cases.
A Johns Hopkins trial in 2021 (Davis et al., JAMA Psychiatry) found an effect size of Cohen's d = 2.3 — unusually large. 71% of participants responded; 54% reached remission. Effects were largely maintained at 12 months, though without a control group at that stage.
An Imperial College London trial the same year compared psilocybin directly against escitalopram (a common SSRI) in 59 people with moderate-to-severe depression. Psilocybin didn't formally "beat" escitalopram on the primary measure — the trial wasn't designed to prove that. But the pattern across every secondary measure was consistent: 70% response with psilocybin versus 48% with escitalopram, 57% remission versus 28%. Better well-being, less emotional blunting, more sense of meaning.
A Swiss trial from the University of Zurich — the most relevant European study — tested a single psilocybin dose against placebo in 52 people with depression. 58% of the psilocybin group responded versus 16% on placebo. 54% reached remission versus 12%. That is a large, meaningful difference.
The honest counterarguments
The most fundamental problem in psilocybin research is that people almost always know whether they received the drug — it's an unmistakable experience. When you know you received the treatment you hoped for, some of your improvement may come from that expectation, not from the medicine itself. This is a real limitation, and regulators have flagged it.
A 2025 European trial called EPISODE tried to control for this by using an active placebo. It missed its primary endpoint — the psilocybin groups and the control group weren't statistically different on the main measure. Secondary measures still showed a signal, but it's a meaningful caution.
A 2026 analysis in JAMA Network Open found that control groups in psilocybin trials tend to improve less than control groups in SSRI or esketamine trials — suggesting the trial designs themselves may inflate psilocybin's apparent advantage.
The evidence is real and growing, but it's not settled. Psilocybin helps a lot of people with depression. We just don't know yet exactly who, or why it works for some and not others.
Why it might work differently from antidepressants
Antidepressants work gradually — adjusting brain chemistry over weeks. If psilocybin works, it seems to work differently, and faster.
Depression often involves a kind of mental rigidity: the same dark thoughts looping, the same patterns repeating, a sense that nothing can change. Psilocybin appears to temporarily disrupt this. During and after a session, the brain's default patterns become less fixed. Networks that were stuck in isolation start talking to each other again.
A 2022 study in Nature Medicine found that psilocybin — but not escitalopram — significantly increased this kind of brain-wide integration, and that this increase correlated with antidepressant effects. (The analysis has been methodologically debated, so it is not the final word, but it points in a consistent direction.)
A 2023 discovery in Nature Neuroscience found that psilocybin also directly activates the brain's key neuroplasticity receptor — TrkB — at roughly 1,000 times the potency of classical antidepressants. This likely explains why effects can begin within a day or two rather than weeks.
Psilocybin seems to create a window in which something can actually shift — not just be suppressed. People who've been through it often say it wasn't about feeling better so much as seeing their situation differently. That shift needs to be worked with, and that's what integration is for.
What actually happens
Before the session (one to three meetings): You and your therapist talk. About your history, what you hope for, what you're afraid of. You learn how to approach difficult experiences if they arise — because they might. The relationship you build here turns out to matter a great deal: a recent analysis of the COMPASS trial data found that the quality of the therapeutic connection independently predicted outcomes, separate from the drug.
The session itself (five to eight hours): You're in a comfortable, private space — not a hospital. You lie down with eyeshades, usually with music. Your therapist is present throughout. The experience doesn't follow a script: it might involve vivid imagery, old memories, emotional release, or a feeling of expanded perspective. It is often not easy. Difficulty is part of the process, not a sign something has gone wrong. A good guide helps you stay with it rather than resist it.
After (multiple integration sessions): The session surfaces things. Integration is the work of understanding what surfaced and bringing it into your daily life. Many practitioners consider this the most important part. Without it, the experience may feel significant but not translate into lasting change.
Is this right for you?
It is not for everyone, and a responsible therapist will tell you that honestly.
It is not suitable if you have:
- A personal or family history of psychosis, schizophrenia, or bipolar I disorder
- Current use of lithium (seizure risk)
- Current use of antipsychotics (will likely block the experience)
- Serious cardiovascular conditions (psilocybin temporarily raises heart rate and blood pressure)
- Active suicidality that needs immediate stabilisation
If you're currently on SSRIs or SNRIs: The interaction is not dangerous, but SSRIs reduce the intensity of the experience, which may reduce how much you get from it. Most protocols ask you to taper off beforehand — under medical supervision, not on your own. Stopping antidepressants suddenly is not safe.
The people who tend to benefit most are those with established depression who have some capacity to reflect, who aren't in acute crisis, and who are genuinely prepared to engage with the process — not just take something and hope. It asks something of you. Most people who have been through it say that is precisely why it works.
If that sounds like where you are, it may be worth taking the next step.
Find a vetted guide or therapist in Europe
What's actually available in Europe right now
Switzerland has had a working framework since 2014. About 100 physicians are authorised to prescribe psilocybin under individual patient authorisations from the federal health authority. In 2024 alone, around 1,660 psychedelic-assisted treatments were delivered — real clinical care, not trials.
Germany launched the EU's first formal Compassionate Use Programme in July 2025, run through the OVID Clinic in Berlin and the Central Institute of Mental Health in Mannheim. Eligibility: failed at least two antidepressant courses. The drug is free; health insurance is expected to cover clinical care. Capacity is limited — around 50 patients in the first year.
The OVID Clinic is also the only private clinic in Europe with a compassionate use psilocybin licence. It is run by Dr Andrea Jungaberle and Dr Henrik Jungaberle, who also lead the MIND Foundation and its APT programme — a 15-month training certification for therapists that is one of the most rigorous in Europe. A therapist who has completed the APT has spent over a year training specifically for this work.
The Czech Republic passed a law in July 2025 — the first EU country to legalise medical psilocybin by statute. It came into force in 2026. Permitted for severe depression, cancer-related depression, and PTSD, in certified facilities with two therapists per session.
The Netherlands has an established scene of experienced practitioners working with psilocybin-containing truffles, which are not scheduled. No formal programme, but real access exists.
The UK is not there yet. Psilocybin remains Class A. Some research access has been simplified, but there is no patient pathway.
A 2026 health economics study found that psilocybin-assisted therapy is cost-effective for treatment-resistant depression compared to standard care — even at current private prices.
Finding someone to work with
The formal programmes above are small. For most people, the path is a qualified private therapist or guide — someone with a clinical background who has trained specifically in psychedelic-assisted work.
These are not retreat facilitators. They are psychiatrists, psychologists, and psychotherapists who have added this specialism to years of conventional clinical practice. They typically work openly — as integration therapists, preparation coaches, or harm reduction specialists. Finding the right person takes some research.
Find a vetted guide or therapist in Europe on Theta Health
Questions people usually have
How long do effects last? The trials show strongest effects in the first weeks, with many people maintaining meaningful improvement at 6 and 12 months. One COMPASS trial confirmed durability through 26 weeks from a single dose. Some people come back for a second session after a year or two. The research can't predict in advance how long it will last for you.
Do I have to stop my antidepressants? SSRIs and SNRIs reduce the experience's intensity, so most protocols involve a supervised taper beforehand. Don't do this on your own — stopping antidepressants abruptly can cause real withdrawal effects and needs medical oversight.
Is it legal? In Switzerland, Germany, and the Czech Republic — yes, through the frameworks above. Elsewhere in Europe, the therapy support work (preparation, integration, harm reduction) is legal throughout. The legal questions are country-specific; a qualified therapist will be clear with you about what applies where you are.
What's the difference between this and a retreat? Retreats work with groups, often in ceremonial formats, with limited individual attention. The clinical protocols that produced these results involve one-to-one therapist contact, serious preparation, and ongoing integration. For serious mental health conditions, the individual setting makes a real difference.
Can it make things worse? Temporarily, during or just after a session, yes — anxiety, emotional difficulty, or a brief worsening of mood are possible. Serious adverse events have been rare across the research. The COMPASS Phase 2b trial reported three cases of suicidal behaviour in the highest-dose group; suicidal ideation appeared across all groups and subscores didn't worsen overall, so these don't represent a psilocybin-specific risk. A responsible provider will screen you carefully, have a safety plan, and check in with you in the days after.
How many sessions? Usually one or two psilocybin sessions, with preparation meetings before and integration sessions after. The whole process typically spans six to twelve weeks. Some people benefit from a single session and that's all they need; others return once or twice more over the years.
How much does it cost? Costs vary by therapist and country — every guide sets their own fees, so always ask directly what is included and what the total will be. As a rough guide: in Switzerland, a full course including preparation and integration typically runs €3,000–€8,000. Germany and the Netherlands are similar for private practitioners. The German compassionate use programme covers the drug cost and potentially clinical care through insurance — but access is very limited. Outside formal programmes, this is a real financial investment, and it is worth having an open conversation about fees before you commit.
How do I know if a therapist is qualified? Clinical background first — psychology, psychiatry, or psychotherapy. Then specific psychedelic training on top of that. In Europe, the MIND Foundation APT programme (Berlin) is one of the more rigorous. Ask them directly: what's your training, how do you screen patients, what's your safety plan, how do you handle integration? Anyone doing this properly will be glad you asked.
Also useful: Our psilocybin dosage guide and calculator covers dose ranges, what affects the experience, and harm-reduction context — useful background if you're still in the research phase.
This article reflects clinical evidence and European regulation as of April 2026. It is for information only and does not constitute medical advice. Psilocybin is a controlled substance in most jurisdictions. Always work with a qualified professional.
Vivien Freeflow · 4/5/2026
Get updates
New articles on psychedelic-assisted therapy in Europe, delivered occasionally. No spam.